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Introduction
Alzheimer’s disease (AD) aﬄ   icts an estimated 24 million 
people in the world, with an expected increase to over 
80  million people by the year 2040 [1]. AD causes an 
insidious and progressive loss of cognitive function and 
independence, taking a heavy personal and ﬁ  nancial toll 
on the patient and the family. Because of the severity and 
increasing prevalence of the disease in the population, it 
is urgent that better treatments be developed.
Th   e only identiﬁ  ed deterministic factors for the develop-
ment of AD are the presence of mutations in one of three 
genes – amyloid precursor protein (APP), presenilin 1 
(PSEN1) or presenilin 2 (PSEN2) – or dupli  cation of APP. 
Approximately 50% of people from these kindreds are 
mutation carriers destined to develop dementia of the 
Alzheimer’s type, generally at an early age (~30 to 
50  years). In the present review, we deﬁ  ne  autosomal-
dominant Alzheimer’s disease (ADAD) as dominantly 
inherited AD with pathological conﬁ  rmation. Other terms, 
such as familial AD and early-onset AD, may encompass 
ADAD, but may also include AD from nondominant causes 
such as the apolipoprotein E4 allele or sporadic Alzheimer’s 
disease (SAD). Although ADAD represents fewer than 1% 
of all AD cases, it is a critically important area of study 
because the pathological features of the disease are similar 
to the more common sporadic form, because causative 
mutations have known bio  chemical consequences that are 
believed to underlie the much more prevalent sporadic form 
of the disease, and because it is possible to identify and 
study pre  symptomatic individuals decades before they are 
destined to develop clinical disease. Th  e opportunity to 
determine the sequence of biomarker changes in pre  symp-
tomatic gene carriers who are destined to develop AD is 
likely to reveal critical infor mation about the pathobiological 
cascade that culminates in symptomatic disease.
Th   e realization that AD is a major and growing public 
health problem with aging populations has added 
urgency to the search for improved therapeutics. Many 
proposed treatments for AD currently target slowing or 
halting of the underlying disease (that is, putative 
disease-modifying interventions), but they are not likely 
to reverse the extensive neuronal death already present at 
the onset of symptoms. For individuals and families at 
risk for ADAD, such interventions have the potential to 
delay or even prevent dementia in asymptomatic indi  vid-
uals, in addition to slowing progression in those with 
symptoms. Th  ese at-risk individuals oﬀ   er a potential 
proof of concept for presymptomatic disease modiﬁ    ca-
tion, with implications for AD more generally.
ADAD families have provided important insights into 
the pathogenesis of AD in the past several decades. 
Discovery of human genetic mutations has facilitated the 
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research today. Knowledge of the molecular mechanisms 
of the identiﬁ  ed mutations has catalyzed identiﬁ  cation of 
the causative pathogenic events in AD in humans. 
Indeed, this avenue of research has provided the most 
compelling case for a unifying theory of AD.
In addition to contributing to advances in the basic 
scientiﬁ  c understanding of AD, ADAD families represent 
an ideal population for preventative and treatment trials 
for several reasons. First, there is near certainty (~100%) 
regarding development of the disease with a known 
mutation that enables prevention studies and increases 
the power of treating minimally or presymptomatic 
patients. Second, the approximate age at which symp-
toms are likely to develop can be predicted in individuals 
who are completely asymptomatic, allowing therapeutic 
trials years or decades before clinical onset. Finally, 
ADAD research participants are highly motivated, rela-
tively young, and have minimal co-morbidities. By 
engaging those at risk for ADAD, uniquely informative 
scientiﬁ   c information about disease progression, bio-
markers and changes due to therapeutic treatments are 
expected to lead to advancements in drug development.
Disease-modifying therapeutics have been largely 
developed with animal models based on human disease-
causing mutations. ADAD caused by known mutations 
most closely resembles those models, and therefore is 
more likely to respond to disease-modifying treatments. 
Results from treatment trials in ADAD will bridge 
cellular and mouse therapeutic research with SAD thera-
peutic research. Because the clinical and pathological 
phenotypes of ADAD are similar to the more common 
late-onset AD, drugs that prove successful in the 
prevention or delay of dementia for ADAD are likely to 
provide guidance for future prevention and disease 
modiﬁ  cation in late-onset AD. Successful implementation 
of prevention and symptomatic studies will therefore 
inform about the causes of AD and will provide guidance 
for future therapeutic development.
In the present review, we present historical and current 
information about ADAD, including: discovery of the 
genetic mutations; clinical, pathological, imaging and 
biomarker ﬁ  ndings; the explosion of understanding about 
AD based on basic science studies of genetic mutations 
and development of AD animal models from the 
mutations; and an international multicenter eﬀ  ort  to 
understand the cascade of events leading to AD toward 
future trials to treat – and even prevent – the onset of 
dementia in those with mutations.
A brief history of autosomal-dominant Alzheimer’s 
disease research
Provocative supportive evidence indicates that Dr Alois 
Alzheimer’s ﬁ  rst case may have been ADAD. Th  is case 
(August D), described in 1906, was early onset, possibly 
familial, and from a region of Germany associated with 
the PSEN2 Volga-German mutation [2]. Th  e ﬁ  rst docu-
mented cases of familial AD were identiﬁ   ed in early-
onset dementia with pathological conﬁ  rmation  [3,4]. 
Other notable early studies identiﬁ  ed pedigrees in which 
more than 10 individuals over ﬁ  ve generations were aﬀ  ected 
by early-onset AD [5]. Aﬀ   ected individuals developed 
symptoms before age 60 with progressive amnesia and 
other signs of cortical cognitive impairment as seen in 
late-onset SAD [6]. Neuropathological exami  na  tion of 
these early cases demonstrated extensive amyloid and 
neuroﬁ  brillary pathology with neuronal loss and gliosis.
In 1963, a case series with early-onset AD in 11 of 26 
children with an aﬀ  ected parent and no aﬀ  ected individ-
uals in the pedigree without an aﬀ  ected parent develop-
ing the disease suggested that early-onset AD was the 
result of a fully penetrant autosomal-dominant mutation 
[7]. Th  e search for a dominant mutation focused on 
chromosome 21, due to the Alzheimer’s-like pathology 
seen in older patients with Down syndrome (trisomy 21). 
In 1987, a genetic linkage study in four large ADAD 
families found a gene locus at 21q11.2 to 21q22.2, but not 
in the 21q22 region associated with the Down syndrome 
phenotype [8]. Th   en, in 1991, a missense point mutation 
(Val-Ile) at codon position 717 was discovered in the APP 
gene in a single family with linkage to chromosome 21 
[9]. Th  is report identiﬁ  ed the speciﬁ  c mutation in this 
family and provided a possible mechanistic link between 
the APP mutations and abnormalities in amyloid process-
ing seen in these families. Most of the variants in APP 
occur between residues 714 and 717 near the putative 
site for γ-secretase cleavage [10]. At least 38 additional 
ADAD APP mutations have since been identiﬁ  ed.
One year after the discovery of mutations in APP as a 
cause of ADAD, four diﬀ   erent laboratories identiﬁ  ed 
another locus for ADAD on 14q24 [11-14]. Th  e gene 
PSEN1  was cloned 3 years later, encoding the protein 
presenilin 1 [15]. Presenilin 1 is a highly conserved 
membrane protein required for γ-secretase to produce 
amyloid-beta (Aβ) from APP [16]. Since the initial ﬁ  nding 
of the PSEN1  mutation, approximately 180 diﬀ  er  ent 
mutations that cause ADAD have been identiﬁ  ed (http://
www.molgen.ua.ac.be/ADMutations/). Within a year of 
cloning PSEN1, a gene with substantial nucleotide and 
amino-acid homology was discovered on the long arm of 
chromosome 1 in two families [15]. Th  is gene, PSEN2, 
appears to account for only a small percentage of ADAD 
cases and may be associated with a later age of onset and 
slower disease progression than mutations in PSEN1 and 
APP.
Th   e discovery of the genetic causes of ADAD catalyzed 
research on the relationship of ADAD to SAD. Th  e  clinical, 
imaging, pathologic and biochemical relation ships  have 
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each following a relatively small number of aﬀ  ected 
families. While the pathogenic cause of ADAD is an 
inherited mutation, the molecular pathogenic causes of 
SAD have not yet been identiﬁ  ed. Th   erefore, although the 
two forms of the disease may have fundamentally 
diﬀ  erent initial pathways, they share a remarkably similar 
pathophysiology. Th  ese descriptions have provided key 
insights into the causes of both SAD and ADAD. Th  e 
characteristics of ADAD compared with the more 
common sporadic late-onset AD are summarized in 
Table 1.
Clinical presentation of ADAD
In broad terms, the clinical presentation of ADAD is very 
similar to that of SAD. Like SAD, most ADAD cases 
present with an insidious onset of episodic memory 
diﬃ   culties followed by inexorable progression of cortical 
cognitive deﬁ  cits. Th  e most obvious diﬀ  erence between 
familial and sporadic cases of AD is the younger age at 
onset in individuals with ADAD mutations. Th  e  youngest 
ages at onset are with PSEN1  mutations; symptoms 
typically ﬁ  rst appear between the ages of 30 and 50 years, 
but some families have individuals aﬀ  ected in their 20s 
[17].  APP pedigrees tend to have a later age at onset, 
typically in the 50s and ranging from 45 to 60 years old. 
Th  e rarer PSEN2 mutations have a wide range of onset 
with some relatively late-onset cases. Overall survival in 
ADAD is similar to that of SAD, with the caveat that 
survival length in very elderly sporadic individuals tends 
to be lower. If younger onset (<65 years old), and 
there  fore healthier, sporadic cases are compared with 
ADAD individuals, their survival is not very diﬀ  erent. 
PSEN1  mutation carriers may have slightly shorter 
survival. Comparisons of disease duration are notoriously 
diﬃ     cult, particularly as recognition of the onset of 
problems may be earlier in familial individuals who are 
aware of their at-risk status – particularly those enrolled 
in longitudinal studies.
Th  e majority of ADAD cases have an amnestic presen-
tation very similar to that seen in sporadic disease, with the 
ﬁ  rst deﬁ  cits being in visual and verbal recall and recog-
nition. Longitudinal studies of unaﬀ  ected at-risk individuals 
have suggested that the earliest neuro  psycho  metric ﬁ  ndings 
involve a fall in verbal memory and performance IQ scores 
[18], with relatively preserved naming [19]. Atypical 
language and behavioral presen  tations occur in a minority 
of both sporadic and familial cases.
Neurological signs and symptoms appear to be more 
common in ADAD. Myoclonus and seizures are both 
relatively more frequent; myoclonus may be a harbinger 
of later seizures. A number of PSEN1  mutations are 
variably associated with a spastic paraparesis (and 
charac  teristic histopathology) and extrapyramidal and 
cerebellar signs.
APP mutations that cluster within the Aβ coding 
domain around positions 692 to 694 do tend to have a 
phenotype that is diﬀ  erent to sporadic disease – cerebral 
hemorrhage is a characteristic feature probably related to 
extensive amyloid angiopathy. Amyloid angiopathy and 
seizures are also a feature of the APP duplication 
pedigrees [20].
Table 1. Comparison of autosomal-dominant Alzheimer’s disease with sporadic Alzheimer’s disease
Measure ADAD  fi  ndings  SAD fi  ndings
Clinical presentation  Episodic (recent) memory and judgment impairment in   Episodic (recent) memory and judgment impairment in
  most; seizures and myoclonus not rare  most; seizures rare in early disease, more common in late 
   disease
Atypical presentation  Yes – behavioral presentations; spastic paraparesis  Yes – behavioral and language presentations; posterior 
   cortical  atrophy
Age of onset  <60 years for most, can be as early as mid-20s;   >60 years for most; <50 years rarely reported
  >60 years rarely reported 
Duration of illness  Average 6 to 9 years  Average 7 to 10 years
Atrophy – volumetric MRI  Hippocampal atrophy, temporo-parietal cortical loss  Hippocampal atrophy, temporo-parietal cortical loss
Hypometabolism – FDG-PET  Temporo-parietal hypometabolism  Temporo-parietal hypometabolism
Amyloid imaging – PiB-PET  Precuneus/posterior cingulate and prefrontal; consistent   Precuneus/posterior cingulate and prefrontal; less
  striatal binding  consistent striatal binding
Pathology  Plaques and tangles in all; CAA in most; cottonwool   Plaques and tangles in all; CAA in most
  plaques in some
CSF Aβ42   Decreased  Decreased
CSF tau, p-tau181  Increased  Increased
Blood Aβ42/Aβ40 ratio  Increased  Variable
Aβ, amyloid-beta; ADAD, autosomal-dominant Alzheimer’s disease; CAA, cerebral amyloid angiopathy; CSF, cerebrospinal fl  uid; FDG, fl  uorodeoxyglucose; MRI, 
magnetic resonance imaging; PET, positron emission tomography; PiB, Pittsburgh Compound B; SAD, sporadic Alzheimer’s disease.
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earlier age at onset, ADAD is remarkably similar to SAD, 
with as yet unexplained heterogeneity being a feature of 
both forms of the disease.
Neuropathology
Th  e principal neuropathological changes in ADAD – 
neuronal loss, neuroﬁ  brillary tangles, senile plaques, and 
cerebral amyloid angiopathy (CAA) – mirror those seen 
in SAD, providing strong support for ADAD as a model 
for studying AD (Figure 1). In vitro and in vivo studies 
have shown that dominant mutations frequently increase 
Aβ42 and Aβ40 deposition and alter the Aβ42/Aβ40 ratio 
[21]. Postmortem studies conﬁ   rmed elevated levels of 
brain Aβ42 in persons with APP mutations compared 
with SAD [22]. APP mutations increase Aβ production 
by diﬀ   erent mechanisms. Mutations adjacent to the β-
secretase cleavage site increase cleavage by β-secretase, 
generating increased Aβ40 and Aβ42 from APP [23]. APP 
mutations around the γ-secretase cleavage sites result in 
modiﬁ   cation of γ-secretase activity, enhancing only the 
production of Aβ42 [24]. PSEN1  and  PSEN2  mutations 
alter the conformation of the γ-secretase complex, increas-
ing production of Aβ42 from APP  [21]. Post  mortem 
studies have shown that PSEN1 and PSEN2 muta tions  are 
related to increased levels of insoluble Aβ42, and to a 
lesser extent insoluble Aβ40, compared with SAD [25-28]. 
A comparable Aβ42/Aβ40 ratio between SAD and PSEN 
mutations has also been reported [29,30], although other 
research has reported a signiﬁ    cantly increased Aβ42/Aβ40 
ratio in PSEN1  and  PSEN2  mutations when compared 
with SAD, primarily due to higher levels of Aβ42 [31].
Distinctive neuropathological features are found in 
some pathology case reports and may be related to 
mutation type. Th   ese variant pathologies may aﬀ  ect the 
pharmacological response, tolerability, and biomarker 
measurements of experimental agents in clinical trials 
into SAD. Th  ese include cottonwool plaques, severe 
CAA, intracerebral hemor  rhage, cerebellar plaques, and 
Lewy bodies. Cottonwool plaques are large, ball-like 
plaques lacking dense amyloid cores that have been 
reported with PSEN1 mutations, especially in mutations 
beyond codon 200 [32]. Cottonwool plaques have been 
associated with spastic paraparesis and seizures [29]. 
CAA is common in SAD, but may be more prominent 
with speciﬁ  c ADAD muta  tions. Th   e Dutch, Flemish, and 
British APP mutations occurring within the Aβ coding 
region typically feature severe CAA, with intracerebral 
hemorrhage occurring in persons with the Dutch 
mutation. Larger and denser Aβ deposits around vessels 
or ring-like plaques staining for Aβ42 instead of Aβ40 
have been reported with some APP mutations compared 
with SAD [33,34]. PSEN1  mutations after codon 200 
show a higher incidence of severe CAA compared with 
SAD [29]. Cerebellar plaques with the British APP and 
some PSEN1 mutations have been reported [22]. Lewy 
body pathology has been reported in the amygdala and 
neocortex with some PSEN1 and PSEN2 mutations [35], 
as has been reported in SAD. Variability in phenotypic 
and patho  logical expression has been reported within 
families, suggesting that genetic or epigenetic factors 
might be exerting disease-modifying eﬀ  ects [31].
Neuroimaging
A growing number of neuroimaging studies have demon-
strated evidence of early alterations in brain structure 
Figure 1. Principal neuropathological changes in autosomal-
dominant Alzheimer’s disease. Sections showing amyloid-beta 
(Aβ)42 and PHF-1 tau detection (top to bottom): presenilin 1 (PS1) 
E280A (male, 62 years old, disease duration 8 years, apolipoprotein 
E3/3); PS1 E280A (male, 50 years old, disease duration 5 years, 
apolipoprotein E3/3); sporadic Alzheimer’s disease (SAD) (female, 
80 years old, disease duration 7 years, apolipoprotein E3/3); SAD 
(female, 84 years old, disease duration 13 years, apolipoprotein E4/4). 
All brain tissues were routinely fi  xed in formalin and were paraffi   n-
embedded. Sections were 12 μm thick. Aβ42 was detected using 
polyclonal antibody C42 (with formic acid pretreatment), kindly 
provided by Dr Takaomi Saido (RIKEN Brain Science Institute, Tokyo, 
Japan). PHF-1 tau was detected using PHF-1 monoclonal antibody 
(with microwave pretreatment), kindly provided by Dr Peter Davies 
(Feinstein Institute of Medical Research, New York, USA).
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tions prior to the onset of clinical dementia. Early 
magnetic resonance imaging (MRI) studies demonstrated 
that hippocampal atrophy was present in presymptomatic 
and early symptomatic carriers, which paralleled the 
develop  ment of verbal or visual memory deﬁ  cits, in a 
pattern similar to that seen in SAD [36]. More severe 
medial-temporal lobe atrophy may be present in sympto-
matic ADAD carriers compared with SAD [37]. Gray-
matter regional volume loss and decreases in magnetiza-
tion transfer ratio have also been reported in mildly 
symptomatic carriers [38]. Longitudinal structural imag-
ing studies have demonstrated an accelerated course of 
atrophy compared with SAD, in both regional-medial 
temporal lobe and whole-brain measures [39-41] and in 
cortical thinning, particularly evident in the precuneus 
and posterior cingulate prior to the diagnosis of dementia 
[42]. Alterations in white matter structure have also been 
demonstrated in presymptomatic and early symptomatic 
carriers, with decreased fractional anisotropy in the 
fornix and widespread areas of brain visualized with 
diﬀ  usion tensor imaging [43].
Presymptomatic alterations in brain perfusion and 
metabolism, similar to the patterns reported in SAD, 
have also been reported among ADAD carriers using 
nuclear medicine techniques, including single photon 
emission tomography [44,45] and positron emission 
tomo  graphy (PET) [46,47]. One study demonstrated early 
glucose ﬂ  uorodeoxyglucose-PET hypometabolism in the 
posterior cingulate cortices, hippocampus and entorhinal 
cortices of presymptomatic carriers of ADAD mutations, 
which was present prior to signiﬁ  cant atrophy in these 
regions [48]. Functional MRI techniques have 
demonstrated alterations in hippocampal activity during 
episodic memory tasks in presymptomatic ADAD 
carriers that appear to occur decades prior to dementia 
[49], similar to the observations in young apolipoprotein 
E ε4 carriers [50,51], however, this observation was not 
replicated in a larger population of ADAD mutation 
carriers in a study employing an implicit novelty 
encoding paradigm [52].
More recently, PET amyloid imaging studies with 
Pittsburgh Compound B (PiB) have revealed evidence of 
ﬁ  brillar Aβ deposition in ADAD, including carriers who 
were up to 10 years younger than the age of onset for 
their family [53-55]. Interestingly, these studies have 
consistently reported elevated levels of PiB retention in 
the striatum of presymptomatic ADAD individuals, 
which occurs more variably in late-onset SAD.
Biomarkers
Th   e biochemical changes in the brain, cerebrospinal ﬂ  uid 
(CSF) and blood of persons with AD have been described 
in detail over the past 30 years. Many biochemical 
changes in the brain have been documented to occur in 
the AD process, with those biomarkers associated with 
amyloid plaques and neuroﬁ  brillary tangles being speciﬁ  c 
for pathologically deﬁ  ned AD [6,56]. Th  e  identiﬁ  cation of 
Aβ as the major component of CAA [57] and amyloid 
deposits in plaques [58] was followed by the ﬁ  nding that 
tau is the major component of neuroﬁ  brillary tangles. In 
addition to AD-speciﬁ  c protein deposition, biochemical 
changes in synaptic, inﬂ   ammatory, oxidative, and cell 
cycle markers occur in the AD brain [59].
Multiple groups have reported that CSF Aβ42 in 
ADAD participants is reduced to approximately one-half 
of normal values [60,61], a ﬁ  nding remarkably similar to 
SAD [62,63]. While decreased Aβ42 appears to have 
remarkable speciﬁ  city for pathologic AD and Aβ amy-
loid  osis in the brain [64], CSF Aβ40 is not consis  tently 
diﬀ   erent in AD individuals compared with normal 
individuals. CSF tau and phospho-tau levels are increased 
almost two-fold in ADAD individuals compared with 
controls [60,61], again mimicking the CSF proﬁ  le in later-
onset SAD. Th  e relative age at which CSF biomarker 
changes occur in ADAD has not yet been adequately 
characterized, although it appears to predate clinical 
symptoms.
Increases in plasma Aβ42 have been consistently found 
in ADAD, while there is little, if any, consistently reported 
diﬀ  erence in SAD [65-67]. Other blood-based biomarkers 
have not yet reproducibly diﬀ  erentiated ADAD or SAD 
from controls.
Mutations
Identiﬁ  cation of mutations in the substrate APP as well as 
in the proteases PSEN1 and PSEN2 that cleave APP to 
produce Aβ peptides provides very strong support for the 
amyloid hypothesis in AD [68]. Th   e mutations in the APP 
gene are clustered around the three cleavage sites 
(Figure  2). Only one mutation (the Swedish mutation) 
increases Aβ generation by increasing β-secretase 
process ing  of  APP. Most of the other mutations aﬀ  ect the 
biophysical properties of the Aβ peptide and have a 
diverse array of eﬀ  ects, but, as indicated in Figure 2, they 
consistently increase the toxic amyloid potential of the 
protein, thereby increasing the tendency of Aβ to oligo-
merize. Th  is is particularly clear for the most abundant 
mutations aﬀ  ecting the γ-secretase cleavage sites, which 
all result in the generation of the longer Aβ42 peptide. 
Th   e rationale for therapeutic strategies that target 
decreas  ing the Aβ generated from the APP protein in 
these families is obviously strong, and β-secretase or γ-
secretase inhibitors are predicted to work as they act on 
the enzymes and not on the APP substrate [69]. For 
immunization strategies, APP mutations in the Aβ 
sequence may or may not interfere with the binding of 
particular antibodies.
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presenilin mutations are scattered throughout the 
presenilin protein, although most are clustered along the 
diﬀ  erent transmembrane domains in the hydrophobic core 
of the protein (Figure 3). Functionally, most presenilin 
mutations cause a loss of function of γ-secretase activity; 
that is, they reduce the cleavage rate of the diﬀ  erent 
substrates of the enzyme [70]. Pathologically, they most 
probably operate in a similar way as the APP mutations by 
enhancing the toxic amyloid potential of the residual Aβ 
peptides that are generated by the mutated presenilin/γ-
secretase. Indeed, although many mutations lower Aβ40 
production, almost all mutations increase or at least do not 
aﬀ  ect the production of the Aβ42 peptide [71]. Th  e  overall 
result is a change in the Aβ42:Aβ40 ratio, which increases 
the tendency to form toxic oligomeric species [72].
γ-Secretase inhibitors may have less eﬀ  ect on mutated 
γ-secretase than on wild-type γ-secretase [73-75]. In 
preparation for treatment trials, individual mutations can 
be tested in vitro for γ-secretase inhibitor eﬀ  ects on γ-
secretase activity. While it is likely that lowering the total 
burden of Aβ peptide might be beneﬁ   cial, caution is 
needed because it is possible that some γ-secretase 
inhibitors could block mainly the wild-type γ-secretase 
while the mutant presenilin remains operational. β-
Secretase inhibitors or vaccination against Aβ avoid this 
particular issue as they target the wild-type β-secretase 
or the wild-type Aβ.
Mouse models
Th  e creation of AD animal models was crucial to the 
development of modern anti-amyloid therapeutic 
Figure 2. Overview of dominantly inherited mutations in the amyloid precursor protein. Amyloid precursor protein (APP) is a type I integral 
membrane protein inserted in the cell membrane (upper part). The APP mutations are all clustered in or around the amyloid-beta (Aβ) peptide 
sequence, and this region is therefore displayed enlarged using the single amino acid code. White circles, mutations found; red font, resulting 
amino acid substitutions. Mutations cluster around the α-secretase, β-secretase and γ-secretase sites as indicated. They have various eff  ects on the 
generation of Aβ as indicated, but their overall eff  ect is an increased tendency to generate toxic species.
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on transgenic mice overexpressing human APP, since no 
naturally occurring animal models fully recapitulate all of 
the pathological and functional deﬁ   cits in AD. Over-
expression of the wild-type APP was insuﬃ   cient to cause a 
relevant phenotype. With the discovery of the familial APP 
mutations, however, several animal models using the 
Swedish, London, Indiana and other mutations have been 
developed and characterized. Most of these mouse models 
show consistent amyloid pathology, but often there is poor 
correlation between the development of morphological 
brain changes of deposition of amyloid plaques and 
disturbances in learning and memory function.
Mouse models with only presenilin 1 or presenilin 2 
mutations have been developed, but they do not develop 
amyloid pathology in spite of increased production of 
Aβ42 [76,77]. Th  e inability of presenilin mutations to 
cause amyloid pathology in mice is most probably due to 
the sequence diﬀ  erences of mouse APP compared with 
human APP, as murine Aβ peptides are less prone to 
aggregation. Accelerated brain pathology was achieved 
by combining the genetic liability of human APP 
mutations with presenilin mutations [78]. In addition, the 
behavioral disturbances are more pronounced in these 
bigenic animals [79].
Transgenic models of ADAD are quite diﬀ  erent from 
human models because of species diﬀ  erences and the 
location and increased amount of expression of the 
mutated protein. Transgenic models can be useful for 
drug development, however, because they develop 
amyloidosis and express altered Aβ peptides similar to 
human carriers of the mutation. Th  erapies that show 
pathological eﬃ     cacy should therefore also be able to 
exhibit similar activity in humans; for example, 
decreasing overall amyloid peptides and normalizing the 
Aβ42:Aβ40 ratio. Because most of the treatments 
currently in clinical trials have been developed in mice 
carrying an ADAD mutation, they are likely to be more 
eﬀ  ective in ADAD compared with SAD. Finally, although 
all of the mouse models demonstrate disturbances of 
amyloid production and metabolism, they are not full 
models of AD. Conclusions about the therapeutic eﬃ   cacy 
Figure 3. Overview of dominantly inherited mutations in presenilin 1. Presenilin contains nine transmembrane domains. The presenilin 1 
mutations (red circles) are scattered over the protein, but most are in the hydrophobic domains of the protein. Green and yellow circles indicate 
whether the eff  ect of the mutation on amyloid-beta (Aβ) production has been investigated: green, mutations that decrease Aβ40 production; 
yellow, mutations that increase Aβ42 production. In all cases, an increase of the Aβ42/Aβ40 ratio has been found.
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cautiously.
Current treatment trials
Current trials for the common form of AD include 
approaches to target Aβ by decreasing production 
[80,81], increasing clearance [82-84], and other attempts 
to ameliorate the toxic eﬀ  ects of the amyloid cascade. 
Alternative targets at various stages of drug development 
include tau, inﬂ  ammation, neurotransmitter modulators, 
and other approaches. Th  e diverse approach to drug 
discovery in AD is helpful for the ﬁ  eld, as there has not 
yet been a successful disease modiﬁ  cation trial. Reasons 
cited for the lack of clinical trial success over the past 
decade include inadequate preclinical models, few trials 
completing phase III studies, few studies with demon-
strated pharmacodynamic activity, treating the disease 
process too late in the disease course, or targeting an 
insigniﬁ   cant mechanism. Treatment trials in ADAD 
provide an opportunity to address several of these 
concerns of treating too little, too late – with designs that 
demonstrate target engagement followed by prevention 
studies to alter the course of changes that occur in the 
disease process.
Despite the opportunity for prevention studies in 
persons destined to develop AD because of ADAD muta-
tions, we are aware of only one such study being per-
formed [85]. Six presymptomatic known PSEN1 muta tion 
carriers are being treated in an open-label fashion with 
HMG-CoA reductase inhibitors (either ator  vastatin or 
simvastatin). In addition to cognitive outcome measures, 
CSF indices (Aβ42, tau, p-tau181, sAPPα, and sAPPβ) are 
being obtained. In a preliminary report, a lowering of 
CSF sAPPα and sAPPβ associated with HMG-CoA 
reductase inhibitors was observed in PSEN1  mutation 
carriers without an eﬀ   ect on Aβ42, tau, or p-tau181. 
Although small in scale, this biomarker study represents 
an important initial step towards larger eﬀ  orts to explore 
preventative interventions in ADAD.
The Dominantly Inherited Alzheimer’s Network
Owing to the geographically dispersed nature of ADAD 
families and the relative rarity of the disease, an 
international network of research centers has been 
established by the National Institute on Aging to ade-
quately power studies in this uniquely informative popu-
lation. Th   is network, formally known as the Dominantly 
Inherited Alzheimer’s Network (DIAN), will enable 
international longitudinal studies of persons with domi-
nantly inherited mutations that cause AD. Th   is is the ﬁ  rst 
large-scale, multicenter, systematic eﬀ  ort to use standard-
ized instruments to identify and uniformly evaluate 
individuals with dominantly inherited AD. Th  e DIAN 
aims to determine the chronological changes in cognition 
and biomarkers in relation to clinical onset and progres-
sion of dementia in a well-characterized and uniformly 
studied group of persons at risk for ADAD. Th  e DIAN 
investigators will assess and quantify the ability of 
clinical, biological and imaging markers to predict and 
track the progression of AD. Th  e DIAN’s overriding 
purpose is to contribute to the search for meaningful 
therapies for AD by helping elucidate the cascade of 
events that lead to dementia of the Alzheimer’s type.
Th  e  speciﬁ  c aims for the DIAN include the following. 
First, to establish an international registry of individuals 
(mutation carriers and noncarriers; presymptomatic and 
symptomatic) who are biological adult children of a 
parent with a known causative mutation for AD in the 
APP, PSEN1, or PSEN2 genes in which the individuals are 
evaluated in a uniform manner at entry and longitudinally 
thereafter. Th  e second aim is to obtain clinical and 
cognitive batteries that comprise the Uniform Data Set of 
the National Institutes of Health-funded Alzheimer’s 
Disease Centers, supplemented by web-based neuro-
psycho  logical tests. A further aim is to implement 
structural, functional, and amyloid imaging protocols (3T 
MRI, ﬂ  uorodeoxyglucose-PET, PiB-PET). Th   e fourth aim 
is to collect biological ﬂ  uids, including blood and CSF, for 
DNA analysis and assays of putative biomarkers of AD, 
including Aβ42 and tau – this will also provide a resource 
for exploratory studies of novel biochemical markers. 
Finally, the DIAN aims to perform uniform histo  patho-
logical examination of cerebral tissue in individuals who 
come to autopsy.
Th   e National Institute on Aging awarded a 6-year grant 
for the DIAN that funds 10 international performance 
sites that combine resources and research participants of 
the individual sites in a uniform and comprehensive 
manner. Currently, over 400 individuals who are 
members of families with a known causative mutation for 
AD (that is, APP, PSEN1, PSEN2) have been identiﬁ  ed 
between the sites and are eligible for participation in the 
DIAN. Over the ﬁ  rst 6 years, sites will recruit, enroll and 
evaluate these individuals to reach a sample size of 400 
participants. Th   e DIAN cohort is predicted to comprise 
80% asymptomatic individuals (with 50% of these being 
mutation carriers and 50% noncarriers) and 20% sympto-
matic individuals. Based on the participant population 
demographics, the DIAN is expected to enroll 50% of 
individuals within 3 years of parental age at disease onset, 
and 30% of individuals within 3 to 10 years before paren-
tal age at disease onset. Th   e DIAN participants will thus 
consist of approxi  mately 160 asymptomatic mutation 
carriers, 80 sympto  matic AD mutation carriers, and 160 
mutation-negative sibling controls.
Data obtained through the DIAN will be used in the 
design and statistical powering of prevention and treat-
ment studies in ADAD. Additionally, white blood cells 
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Alzheimer’s Disease to establish immortalized lympho-
blastoid cell lines for use in a variety of investigations, 
including in vitro studies to characterize the pharmaco-
dynamic properties of putative anti-AD agents and their 
applicability in both ADAD and SAD. Th   e DIAN will also 
provide the infrastructure for the recruitment and 
retention of subjects, which is critical for the successful 
performance of clinical trials in this rare, widely 
dispersed, and informative population.
Design of the DIAN clinical trials
An additional scientiﬁ  c aim for the DIAN is to evaluate 
potential disease-modifying compounds for the treat-
ment of AD. To this end, the DIAN formed a Clinical 
Trials Committee to direct the design and management 
of interventional therapeutic trials of DIAN participants. 
Th  e committee will assist in the design and implemen-
tation of trials that have the highest likelihood of success 
while providing advancement of treatments, scientiﬁ  c 
understanding and clinical eﬀ  ects of proposed therapies. 
Speciﬁ   cally, the committee’s aims are to evaluate trial 
designs to determine the impact of interventions on 
biomarker, cognitive, and clinical measures in ADAD, to 
determine which therapeutic targets are most amenable 
to treatment at diﬀ  erent stages of AD, and to test the 
hypotheses for the causes of AD (for example, amyloid 
hypothesis) through therapeutic treatment trials.
Testing interventions for the prevention of AD in 
presymptomatic persons with inherited ADAD muta-
tions oﬀ  ers potential for medical and scientiﬁ  c advances, 
but also presents a number of challenges – ethically, 
scientiﬁ  cally, and logistically. ADAD participants tend to 
be highly motivated for research, perhaps due in large 
part to altruism. Th   at is, they frequently express the hope 
that even if their participation does not beneﬁ  t them-
selves, perhaps it will beneﬁ   t their family members, 
including their progeny. One key design challenge is the 
fact that most individuals at risk of carrying an ADAD 
mutation have not chosen to have genetic testing. In a 
clinical series of 251 persons at risk for ADAD or fronto-
temporal lobar degeneration due to mutations in the 
MAPT gene, only 8.4% requested such testing [86].
Th   e DIAN investigators aim to explore disease-modify-
ing treatments in ADAD mutation carriers. Th  e  ultimate 
goal is to postpone or prevent the onset of AD symptoms, 
or to slow the progression of symptoms. Th  e limited 
number of potential participants, however, limits the 
feasibility of trials with traditional cognitive or clinical 
outcomes. Th   e DIAN will pursue a strategy of assessing 
the impact of putative disease-modifying treatments on 
biomarkers of AD in combination with sensitive measures 
of cognition. Candidate biomarkers include molecular 
imaging (amyloid PET scanning), functional imaging 
(ﬂ  uorodeoxyglucose-PET) and structural imaging (volu-
metric MRI measures), as well as biochemical measures 
in CSF (for example, tau, phospho-tau and Aβ42). 
Although no biomarker has been validated as a surrogate 
outcome for regulatory purposes, these biomarkers 
represent plausible candidate surrogate outcomes being 
pursued by AD trialists. Th  e rationale for accepting 
surrogate markers with cognitive improvements as viable 
endpoints is compelling in this genetically determined 
population.
As the number of preventative studies that might be 
performed in persons carrying familial AD mutations 
will be limited, the optimum choice of intervention is 
critical. Medica  tions that prevent neurodegeneration by 
targeting the causative mechanisms are ideal as they 
might both prevent the development of pathology and 
slow progres  sion after onset. Active or passive immuno-
therapy or γ-secretase or β-secretase inhibitors may 
fulﬁ   ll these criteria. Potential hazards include compli-
cations related to established amyloid angiopathy (for 
example, vaso  genic edema), which may be increased in 
some ADAD mutations, teratogenicity, and other 
unknown risks of chronic exposure.
Statistical design and analyses
As only a minority of presymptomatic persons at risk for 
ADAD mutations asks to know their genetic status, 
enrollment of mutation carriers into prevention studies 
presents a challenge. Th  e availability of treatment trials 
will undoubtedly inﬂ  uence the decision to obtain genetic 
testing. If genetic testing is required for a treatment trial, 
participants will need to consider testing for mutation 
status in order to participate in a study in which they may 
receive a medication (or placebo) that may help prevent 
the illness but could also have signiﬁ  cant side eﬀ  ects. An 
alternative approach would be to open enrollment to all 
persons at risk, to not report genetic testing, and to only 
randomize active drug to mutation carriers with 
noncarriers receiving blinded placebo. In such a study, 
the occurrence of side eﬀ  ects might unblind participants 
to their treatment group and therefore to their mutation 
status. Informed consent for such a trial would need the 
equivalent of presymptomatic genetic counseling for this 
possibility.
Th  e gold standard for demonstrating eﬃ   cacy  of  an 
intervention is the prospective randomized, blinded, 
placebo-controlled study. Additionally, studies might be 
designed that feature open-label extensions after a 
prespeciﬁ   ed time period and/or a clinical endpoint is 
reached (such as diagnosis of dementia).
Well-established AD biomarkers, including CSF, PiB, 
and MRI markers, can be used as endpoints in clinical 
trials on DIAN presymptomatic mutation carriers. Th  e 
objective of such trials is to determine the eﬃ   cacy of 
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these biomarkers. In addition, cognitive and global 
function measures (for example, Clinical Dementia 
Rating sum of boxes) can be used in clinical trials on 
DIAN symptomatic participants. Given the potential 
heterogeneity of the population, baseline co-variants may 
be critical to maximize eﬃ   ciency. In a prevention trial of 
presymptomatic ADAD participants, sensitive cognitive 
measures may be used in combination with biomarker 
changes. Alternatively, the time to the onset of mild 
cognitive impairment or AD can be reasonably used as 
an eﬃ   cacy endpoint, especially if participants are chosen 
with appropriate estimates of their age of onset so that 
enough participants will develop AD during the designed 
length of follow-up to satisfy the statistical power 
requirement. Th  e high-risk period immediately before 
clinical and cognitive decline can be determined by the 
use of biomarkers together with family history and age.
Th   e ongoing DIAN longitudinal study provides 
important baseline and rate of change data for clinical, 
cognitive, imaging and other biomarkers. Th   ese data will 
increase the ability to power and design clinical trials, 
and will also provide a pretreatment rate of change for 
analysis of treatment eﬀ  ects. In general, an increase of 
either the study duration or the frequency and precision 
of repeated measures will decrease the within-subject 
variability and will improve the precision of parameter 
estimates or statistical power over time [87]. In preven-
tion trials in presymptomatic DIAN participants, the 
duration of the trial as well as the age window of 
participants relative to their parents’ age of disease onset 
is crucial to allow for adequate biomarker and cognitive 
change to be detected.
Plans for initial DIAN therapeutic trials include 
identifying optimal anti-amyloid candidate interventions 
in development. If indicated, the suitability of speciﬁ  c 
candidate agents may be ﬁ   rst assessed with short-
duration cerebrospinal ﬂ  uid biomarker studies to conﬁ  rm 
target engagement. Th   e study population may include all 
participants at risk, or a subset with more imminent risk 
as suggested by biomarkers or expected age of onset; 
both symptomatic and presymptomatic individuals may 
be included. Study designs that may be implemented 
include randomized controlled trials with parallel group 
designs, lasting approximately 2 years. After completion 
of the placebo-controlled period, all participants can be 
oﬀ   ered open-label treatment with continued regular 
assess ments.  Th  e primary outcome measure may be a 
change in amyloid PET signal; this measure provides 
adequate power to demonstrate a treatment eﬀ  ect with 
group sizes of only 20 to 30 participants [82], and allows 
a clinically heterogeneous study population. Secondary 
outcomes would include other imaging and biochemical 
biomarkers, as well as cognitive and clinical assessments.
Conclusion
A historical precedent highlights what is possible in the 
approach to prevent end organ damage by early 
intervention. Although there are challenges in designing 
and implementing presymptomatic treatment trials for 
an early-onset genetic disease, we are encouraged by 
similar successful trials in vascular disease. Th  e ﬁ  rst 
clinical improvement in statin treatment for hyper-
cholesterolemia was demonstrated in familial hyper-
choles  terolemia, a genetic, early-onset aggressive form of 
the more common later-onset hypercholesterol  emia that 
ultimately leads to myocardial infarction and stroke [88]. 
After 4 to 8 weeks of treatment with mevastatin, patients 
with familial hypercholesterolemia demonstrated resolv-
ing vascular bruits and disappearance of tendonous 
xanthomas [89]. Further, treatment with mevastatin 
decreased cholesterol levels in familial hypercholes-
terolemia patients as well as in nonfamilial hyperlipid-
emic patients. Taken together, these observations 
provided the ﬁ  rst biological evidence of a direct eﬀ  ect of 
a statin on cholesterol metabolism and clinical ﬁ  ndings. 
Th   ese early biomarker studies heralded the future success 
of a class of anti-cholesterol drugs called statins in 
reducing heart attacks and strokes for millions of patients 
worldwide. So too may studies of anti-amyloid treatments 
in ADAD also lead to breakthroughs that allow for highly 
eﬀ  ective therapies against SAD.
Th   erapeutic trials in ADAD are highly likely to produce 
critical scientiﬁ  c information, test fundamental theories, 
bridge basic science with clinical trials, accelerate 
therapeutic development for SAD and, perhaps most 
importantly, oﬀ  er a chance for ADAD mutation carriers 
to improve their lives and their children’s lives.
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